Profound Medical Corp. (PROF)

Market Cap	138.35M
Revenue (ttm)	11.86M
Net Income (ttm)	-31.96M
Shares Out	30.04M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,501
Open	4.800
Previous Close	4.980
Day's Range	4.400 - 4.990
52-Week Range	3.895 - 11.420
Beta	0.26
Analysts	Strong Buy
Price Target	11.50 (+148.38%)
Earnings Date	May 8, 2025

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: PROF
• Website: https://www.profoundmedical.com

Financial Performance

In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 148.38% from the latest price.

Price Target

$11.5

(148.38% upside)

Analyst Consensus: Strong Buy